The global drug discovery services market size is calculated at USD 24.26 billion in 2025 and is forecasted to reach around USD 79.71 billion by 2034, accelerating at a CAGR of 14.13% from 2025 to 2034. The North America market size surpassed USD 9.35 billion in 2024 and is expanding at a CAGR of 14.26% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug Discovery Services Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug Discovery Services Market, by Process Type
8.1.1. Target Selection
8.1.1.1. Market Revenue and Forecast
8.1.2. Target Validation
8.1.2.1. Market Revenue and Forecast
8.1.3. Hit to Lead Identification
8.1.3.1. Market Revenue and Forecast
8.1.4. Lead Optimization
8.1.4.1. Market Revenue and Forecast
8.1.5. Candidate Validation
8.1.5.1. Market Revenue and Forecast
9.1. Drug Discovery Services Market, by Drug Type
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast
9.1.2. Biologics
9.1.2.1. Market Revenue and Forecast
10.1. Drug Discovery Services Market, by Type
10.1.1. DMPK
10.1.1.1. Market Revenue and Forecast
10.1.2. Biology Services
10.1.2.1. Market Revenue and Forecast
10.1.3. Medicinal Chemistry
10.1.3.1. Market Revenue and Forecast
11.1. Drug Discovery Services Market, by Therapeutic Area Type
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast
11.1.3. Diabetes
11.1.3.1. Market Revenue and Forecast
11.1.4. Neurology
11.1.4.1. Market Revenue and Forecast
11.1.5. Respiratory Diseases
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Process
12.1.2. Market Revenue and Forecast, by Drug Type
12.1.3. Market Revenue and Forecast, by Type
12.1.4. Market Revenue and Forecast, by Therapeutic Area Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Process
12.1.5.2. Market Revenue and Forecast, by Drug Type
12.1.5.3. Market Revenue and Forecast, by Type
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Process
12.1.6.2. Market Revenue and Forecast, by Drug Type
12.1.6.3. Market Revenue and Forecast, by Type
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Process
12.2.2. Market Revenue and Forecast, by Drug Type
12.2.3. Market Revenue and Forecast, by Type
12.2.4. Market Revenue and Forecast, by Therapeutic Area Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Process
12.2.5.2. Market Revenue and Forecast, by Drug Type
12.2.5.3. Market Revenue and Forecast, by Type
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Process
12.2.6.2. Market Revenue and Forecast, by Drug Type
12.2.6.3. Market Revenue and Forecast, by Type
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Process
12.2.7.2. Market Revenue and Forecast, by Drug Type
12.2.7.3. Market Revenue and Forecast, by Type
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Process
12.2.8.2. Market Revenue and Forecast, by Drug Type
12.2.8.3. Market Revenue and Forecast, by Type
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Process
12.3.2. Market Revenue and Forecast, by Drug Type
12.3.3. Market Revenue and Forecast, by Type
12.3.4. Market Revenue and Forecast, by Therapeutic Area Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Process
12.3.5.2. Market Revenue and Forecast, by Drug Type
12.3.5.3. Market Revenue and Forecast, by Type
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Process
12.3.6.2. Market Revenue and Forecast, by Drug Type
12.3.6.3. Market Revenue and Forecast, by Type
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Process
12.3.7.2. Market Revenue and Forecast, by Drug Type
12.3.7.3. Market Revenue and Forecast, by Type
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Process
12.3.8.2. Market Revenue and Forecast, by Drug Type
12.3.8.3. Market Revenue and Forecast, by Type
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Process
12.4.2. Market Revenue and Forecast, by Drug Type
12.4.3. Market Revenue and Forecast, by Type
12.4.4. Market Revenue and Forecast, by Therapeutic Area Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Process
12.4.5.2. Market Revenue and Forecast, by Drug Type
12.4.5.3. Market Revenue and Forecast, by Type
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Process
12.4.6.2. Market Revenue and Forecast, by Drug Type
12.4.6.3. Market Revenue and Forecast, by Type
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Process
12.4.7.2. Market Revenue and Forecast, by Drug Type
12.4.7.3. Market Revenue and Forecast, by Type
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Process
12.4.8.2. Market Revenue and Forecast, by Drug Type
12.4.8.3. Market Revenue and Forecast, by Type
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Process
12.5.2. Market Revenue and Forecast, by Drug Type
12.5.3. Market Revenue and Forecast, by Type
12.5.4. Market Revenue and Forecast, by Therapeutic Area Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Process
12.5.5.2. Market Revenue and Forecast, by Drug Type
12.5.5.3. Market Revenue and Forecast, by Type
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Process
12.5.6.2. Market Revenue and Forecast, by Drug Type
12.5.6.3. Market Revenue and Forecast, by Type
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Type
13.1. Abbott Laboratories Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Advinus Therapeutics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Agilent Technologies Ubiquigent
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Albany Molecular Research Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca PLC
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aurigene
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bayer AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Charles River Laboratories International
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. ChemBridge Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Covance
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample